Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction

European Heart Journal: Acute Cardiovascular Care

Volumn 3, Issue 2, 2014, Pages 110-117

  de Waha, Suzanne ^a   Eitel, Ingo ^a   Desch, Steffen ^a   Fuernau, Georg ^a   Lurz, Philipp ^a   Schuler, Gerhard ^a   Thiele, Holger ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Antiplatelets; infarct size; microvascular obstruction; myocardial infarction; reperfusion

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

AGED; ANALOGS AND DERIVATIVES; FEMALE; HEART CATHETERIZATION; HEART MUSCLE REPERFUSION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROVASCULATURE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PROCEDURES; TIME TO TREATMENT; TREATMENT OUTCOME;

AGED; CARDIAC CATHETERIZATION; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROVESSELS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84919326731     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872614520752     Document Type: Article

References (30)

1. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78–e140.
2. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–2619.
3. Koul S, Smith JG, Schersten F, et al. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011; 32: 2989–2997.
4. Dorler J, Edlinger M, Alber HF, et al. Clopidogrel pretreatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32: 2954–2961.
5. Vlaar PJ, Svilaas T, Damman K, et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. Circulation 2008; 118: 1828–1836.
6. Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and metaanalysis. JAMA 2012; 308: 2507–2516.
7. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100: 1992– 2002.
8. Rochitte CE, Lima JAC, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998; 98: 1006–1014.
9. de Waha S, Desch S, Eitel I, et al. Impact of early versus late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction – a comparison to traditional prognostic markers. Eur Heart J 2010; 31: 2660–2668.
10. Larose E, Rodes-Cabau J, Pibarot P, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol 2010; 55: 2459–2469.
11. Thiele H, Eitel I, Meinberg C, et al. Randomised comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction). JACC Cardiovasc Interv 2011; 4: 605–614.
12. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of highdose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo- Controlled, Randomised Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 2010; 55: 2201–2209.
13. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2008; 118: 49–57.
14. Kwong R, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting without signs or symptoms of coronary artery disease. Circulation 2006; 113: 2733–2743.
15. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 2004; 110: e506–e510.
16. Killip T and Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457–464.
17. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. N Engl J Med 1985; 312: 932–936.
18. Thiele H, Kappl MJ, Conradi S, et al. Reproducibility of chronic and acute infarct size measurement by delayed enhancement magnetic resonance imaging. J Am Coll Cardiol 2006; 47: 1641–1645.
19. Desch S, Engelhardt H, Meissner J, et al. Reliability of myocardial salvage assessment by cardiac magnetic resonance imaging in acute reperfused myocardial infarction. Int J Cardiovasc Imag 2012; 28: 263–272.
20. Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomised CIPAMI trial. Clin Res Cardiol 2011; 101: 305–312.
21. Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008; 117: 3152–3156.
22. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281–292.
23. Thiele H, Kappl MJ, Linke A, et al. Influence of time-totreatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J 2007; 28: 1433–1439.
24. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomised trial. JAMA 2012; 307: 1817–1826.
25. Kaltoft A, Bottcher M, Nielsen SS, et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomised, controlled trial. Circulation 2006; 114: 40–47.
26. Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013; 369: 1587–1597.
27. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.
28. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.
29. Montalescot G, Lassen JF, Hamm CW, et al. Ambulance or in-catheterisation laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomised, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J 2013; 165: 515–522.
30. Eitel I, Wöhrle J, Suenkel H, et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous intervention in ST-elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. J Am Coll Cardiol 2013; 61: 1447–1454.